BioSig Technologies, Inc., a medical device company, has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace. BioSig is preparing to commercialize its PURE EP system, a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making real-time clinical decisions by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying areas of tissue to destroy that otherwise create a heart rhythm disturbance. For more information, visit the company’s website at www.biosigtech.com.